JP2018510139A - フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法 - Google Patents

フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法 Download PDF

Info

Publication number
JP2018510139A
JP2018510139A JP2017544035A JP2017544035A JP2018510139A JP 2018510139 A JP2018510139 A JP 2018510139A JP 2017544035 A JP2017544035 A JP 2017544035A JP 2017544035 A JP2017544035 A JP 2017544035A JP 2018510139 A JP2018510139 A JP 2018510139A
Authority
JP
Japan
Prior art keywords
compound
fold
compounds
integrin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017544035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510139A5 (enExample
Inventor
ベン シー． アスキュー
ベン シー． アスキュー
建 古谷
建 古谷
Original Assignee
サイフルーア ライフ サイエンシズ インコーポレイテッド
サイフルーア ライフ サイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイフルーア ライフ サイエンシズ インコーポレイテッド, サイフルーア ライフ サイエンシズ インコーポレイテッド filed Critical サイフルーア ライフ サイエンシズ インコーポレイテッド
Publication of JP2018510139A publication Critical patent/JP2018510139A/ja
Publication of JP2018510139A5 publication Critical patent/JP2018510139A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017544035A 2015-02-19 2016-02-19 フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法 Pending JP2018510139A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118303P 2015-02-19 2015-02-19
US62/118,303 2015-02-19
PCT/US2016/018612 WO2016134223A2 (en) 2015-02-19 2016-02-19 Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020171641A Division JP7191299B2 (ja) 2015-02-19 2020-10-12 フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法

Publications (2)

Publication Number Publication Date
JP2018510139A true JP2018510139A (ja) 2018-04-12
JP2018510139A5 JP2018510139A5 (enExample) 2019-03-14

Family

ID=56689184

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017544035A Pending JP2018510139A (ja) 2015-02-19 2016-02-19 フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法
JP2020171641A Active JP7191299B2 (ja) 2015-02-19 2020-10-12 フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020171641A Active JP7191299B2 (ja) 2015-02-19 2020-10-12 フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法

Country Status (13)

Country Link
US (5) US9790222B2 (enExample)
EP (2) EP3259271B1 (enExample)
JP (2) JP2018510139A (enExample)
KR (1) KR102647026B1 (enExample)
CN (2) CN114805342A (enExample)
AU (1) AU2016219906B2 (enExample)
BR (1) BR112017017888A2 (enExample)
CA (1) CA2976634C (enExample)
ES (1) ES2892954T3 (enExample)
IL (1) IL253873A0 (enExample)
RU (1) RU2017132433A (enExample)
TW (1) TWI736529B (enExample)
WO (1) WO2016134223A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522269A (ja) * 2018-04-27 2021-08-30 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリン標的化リガンドとその使用

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8901144B2 (en) * 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
KR102216091B1 (ko) 2013-02-07 2021-02-16 사이플루어 라이프 사이언시즈, 인크 플루오르화 인테그린 길항제
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
EP3259271B1 (en) * 2015-02-19 2021-05-05 SciFluor Life Sciences, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
US20180110762A1 (en) * 2015-03-26 2018-04-26 Merck Sharp & Dohme Corp Compositions Methods for Treating Chronic Kidney Disease
BR112017023432A2 (pt) * 2015-04-30 2018-07-24 Scifluor Life Sciences Inc Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2017189828A1 (en) 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
MA46745A (fr) 2016-11-08 2021-03-31 Bristol Myers Squibb Co Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
US10851098B2 (en) 2016-11-08 2020-12-01 Bristol-Myers Squibb Company Azole amides and amines as alpha v integrin inhibitors
CA3042707A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as .alpha.v integrin inhibitors
WO2018089355A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
AU2017359030A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors
AU2018227417B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW201835078A (zh) 2017-02-28 2018-10-01 美商萊築理公司 αvβ6整合蛋白之抑制劑
WO2018183795A1 (en) * 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds
US11292802B2 (en) 2017-11-07 2022-04-05 Bristol-Myers Squibb Company Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
PL3844162T3 (pl) * 2018-08-29 2025-06-09 Morphic Therapeutic, Inc. Inhibitory integryny alfa v beta 6
EP4146264A4 (en) * 2020-05-07 2024-07-24 Pliant Therapeutics, Inc. Treatment of respiratory diseases with amino acid compounds
WO2021231581A1 (en) 2020-05-12 2021-11-18 Scifluor Life Sciences, Inc. METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED α V INTEGRIN ANTAGONISTS
CN116390754A (zh) * 2020-10-20 2023-07-04 莱兰斯坦福初级大学评议会 用于过继细胞治疗的可注射水凝胶

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508374A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
JP2004500326A (ja) * 1999-06-02 2004-01-08 メルク　エンド　カムパニー　インコーポレーテッド αｖインテグリン受容体拮抗薬
JP2004508401A (ja) * 2000-09-18 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド シクロオキシゲナーゼ−２阻害剤およびインテグリンアルファ−ｖアンタゴニストの組合せを用いる炎症の治療
JP2007507440A (ja) * 2003-10-01 2007-03-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗線維症薬としてのαｖβ３及びαｖβ６インテグリンアンタゴニスト
WO2014124302A1 (en) * 2013-02-07 2014-08-14 Scifluor Life Sciences, Llc Fluorinated integrin antagonists

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307483A4 (en) 1987-03-30 1990-02-06 Anritsu Corp LIGHT SIGNAL GENERATOR AND CALIBRATION METHOD OF A LIGHT POWER MEASURING DEVICE WITH THIS LIGHT SIGNAL GENERATOR.
CA1318254C (en) 1988-01-06 1993-05-25 Munehiro Tomikawa Inhibitory agent of hepatic fibrosis containing pantethine
WO1992017065A2 (en) 1991-04-01 1992-10-15 Duke University Method of inhibiting fibrosis
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
JP3818322B2 (ja) 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
US6544767B1 (en) 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US5736357A (en) 1994-10-27 1998-04-07 Arris Pharmaceutical Cathespin O protease
US5645839A (en) 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US6211184B1 (en) 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
CN1284955A (zh) 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
DE69829996T2 (de) 1997-12-17 2006-02-23 Merck & Co., Inc. (A New Jersey Corp.) Integrin-rezeptor-antagonisten
US6117445A (en) 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
US6420396B1 (en) * 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6291503B1 (en) 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP4787447B2 (ja) 2000-01-20 2011-10-05 メルク・シャープ・エンド・ドーム・コーポレイション αｖインテグリン受容体拮抗薬
JP2003520271A (ja) 2000-01-24 2003-07-02 メルク エンド カムパニー インコーポレーテッド αｖインテグリン受容体拮抗薬
WO2001062292A1 (en) 2000-02-22 2001-08-30 Suntory Limited Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
GB0011817D0 (en) 2000-05-16 2000-07-05 Pharmacia & Upjohn Spa Antagonists of integrin receptors
EP1315501B1 (en) 2000-07-26 2007-02-07 Merck & Co., Inc. Alpha v integrin receptor antagonists
JP2004509123A (ja) 2000-09-14 2004-03-25 メルク　エンド　カムパニー　インコーポレーテッド アルファνインテグリン受容体アンタゴニスト
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
US7074930B2 (en) 2001-11-06 2006-07-11 Merck & Co., Inc Amine salts of an integrin receptor antagonist
US20040053968A1 (en) 2001-12-28 2004-03-18 Hartman George D. Methods and compositions for treating peridontal disease
EP1551401A4 (en) 2002-09-20 2006-03-22 Merck & Co Inc MANNITOL FORMULATION FOR AN INTEGRIN RECEPTOR ANTAGONIST
JP2006518333A (ja) 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
CA2715034C (en) * 2008-03-14 2016-12-06 Visen Medical, Inc. Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
WO2011060395A1 (en) 2009-11-16 2011-05-19 Schering Corporation Cyclic ureas useful as hiv inhibitors
EP3318561B1 (en) 2010-05-26 2021-12-22 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
BR112013028914B1 (pt) 2011-05-09 2022-02-15 Allegro Pharmaceuticals, Inc Uso de um peptídeo inibidor de integrina que consiste em glicinil-arginil-glicinil-cisteico (ácido)-treonil-prolina-cooh para tratar edema macular
CA2840491A1 (en) 2011-06-28 2013-01-03 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sorafenib
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
EP3259271B1 (en) 2015-02-19 2021-05-05 SciFluor Life Sciences, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
BR112017023432A2 (pt) 2015-04-30 2018-07-24 Scifluor Life Sciences Inc Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
WO2018183795A1 (en) 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508374A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
JP2004500326A (ja) * 1999-06-02 2004-01-08 メルク　エンド　カムパニー　インコーポレーテッド αｖインテグリン受容体拮抗薬
JP2004508401A (ja) * 2000-09-18 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド シクロオキシゲナーゼ−２阻害剤およびインテグリンアルファ−ｖアンタゴニストの組合せを用いる炎症の治療
JP2007507440A (ja) * 2003-10-01 2007-03-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗線維症薬としてのαｖβ３及びαｖβ６インテグリンアンタゴニスト
WO2014124302A1 (en) * 2013-02-07 2014-08-14 Scifluor Life Sciences, Llc Fluorinated integrin antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMES ADAMS, ACS MED. CHEM. LETT., vol. 5, JPN6019045467, 2014, pages 1207 - 1212, ISSN: 0004281929 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522269A (ja) * 2018-04-27 2021-08-30 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリン標的化リガンドとその使用
JP7704529B2 (ja) 2018-04-27 2025-07-08 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリン標的化リガンドとその使用

Also Published As

Publication number Publication date
TW201643161A (zh) 2016-12-16
CN114805342A (zh) 2022-07-29
ES2892954T3 (es) 2022-02-07
US20210277000A1 (en) 2021-09-09
AU2016219906A1 (en) 2017-09-07
CA2976634C (en) 2023-10-17
US11685738B2 (en) 2023-06-27
RU2017132433A (ru) 2019-03-19
US20240092775A1 (en) 2024-03-21
WO2016134223A2 (en) 2016-08-25
US20160244447A1 (en) 2016-08-25
IL253873A0 (en) 2017-10-31
JP2021008511A (ja) 2021-01-28
CN107531699A (zh) 2018-01-02
US10301307B2 (en) 2019-05-28
AU2016219906B2 (en) 2020-10-01
EP3259271B1 (en) 2021-05-05
US12286432B2 (en) 2025-04-29
EP3259271A4 (en) 2018-07-11
RU2017132433A3 (enExample) 2019-03-25
WO2016134223A3 (en) 2016-10-20
KR102647026B1 (ko) 2024-03-12
CA2976634A1 (en) 2016-08-25
EP3259271A2 (en) 2017-12-27
EP3925959A1 (en) 2021-12-22
BR112017017888A2 (pt) 2018-04-10
JP7191299B2 (ja) 2022-12-19
US20170369490A1 (en) 2017-12-28
KR20170117578A (ko) 2017-10-23
US9790222B2 (en) 2017-10-17
TWI736529B (zh) 2021-08-21
US20190225609A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
JP7191299B2 (ja) フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法
JP6494528B2 (ja) フッ化インテグリンアンタゴニスト
US10118929B2 (en) Nonanoic and decanoic acid derivatives and uses thereof
HK40066388A (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1243061A1 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
HK1241361B (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1248677B (en) Fluorinated integrin antagonists
HK1217696B (en) Fluorinated integrin antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200610